Abstract: The present disclosure relates to formulations of proton pump inhibitors such as omeprazole or esomeprazole including their salts or hydrated salts, such as esomeprazole sodium, esomeprazole magnesium or esomeprazole magnesium dihydrate, and methods of use in treating ulcers in equines and other veterinary animals The disclosure also relates to injectable formulations of proton pump inhibitors such as omeprazole or esomeprazole including their salts or hydrated salts, such as esomeprazole sodium, esomeprazole magnesium, or esomeprazole magnesium dihydrate, which have a small particle size, such as a median particle size of less than 10 ?m or less than 5 ?m.

Abstract: Pharmaceutical formulations and methods useful for the treatment of anorexia and the stimulation of appetite and weight gain, and the management of weight loss in dogs and cats.

Abstract: Pharmaceutical formulations and methods useful for the treatment of anorexia and the stimulation of appetite and weight gain, and the management of weight loss in dogs and cats.

Abstract: The present invention provides improved method of preparing a 4-O-alkyl chromogenic ketoside of N-acetylneuraminic acid (Neu5Ac) and a 7-O-alkyl chromogenic ketoside of N-acetylneuraminic acid (Neu5Ac) for use in the selective detection of various influenza viruses and parainfluenza viruses. The ketosides are substrates that are selectively cleaved by a neuraminidase on the virus to be detected, but not by neuraminidases found on other viruses or on bacteria, or on the cells of the host. The syntheses are efficient and provide large quantities of the ketosides for commercial development. The synthesis includes a step of alkylating the 4- or 7-hydroxyl groups of a protected alkyl ester alkyl ketoside derivative of Neu5Ac by processes that include contacting the derivative with a composition comprising an alkyl halide to form a 4- or a 7-O-alkyl protected alkyl ester alkyl ketoside derivative of Neu5Ac.

Abstract: The present invention provides an improved method of preparing a 4,7-di-O-alkyl chromogenic ketoside of N-acetylneuraminic acid (Neu5Ac) for use in detecting influenza virus types A and B. The ketosides are substrates that are selectively cleaved by a neuraminidase on influenza virus, but not be neuraminidases found on other viruses or on bacteria. The synthesis is efficient and provides large quantities of the ketoside for commercial development. The synthesis includes a step of alkylating the 4- and 7-hydroxyl groups of a protected alkyl ester alkyl ketoside derivative of Neu5Ac by a process that comprises contacting the derivative with a composition comprising an alkyl halide to form a 4,7-di-O-alkyl protected alkyl ester alkyl ketoside derivative of Neu5Ac. The synthesis alternatively includes protecting the 8- and 9-hydroxyl groups of an alkyl ester alkyl ketoside derivative of Neu5Ac by forming an 8,9-epoxide protected alkyl ester alkyl ketoside derivative of Neu5Ac.

Abstract: Disclosed are novel oligosaccharide glycosides having mammalian immunosuppressive and tolerogenic properties, pharmaceutical compositions containing such oligosaccharide glycosides and to methods of using such oligosaccharide glycosides to modulate cell-mediated immune responses in a mammal.